{
    "clinical_study": {
        "@rank": "15079", 
        "arm_group": {
            "arm_group_label": "Pioglitazone 15 mg to 30 mg, orally, once daily"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and efficacy of long-term treatment\n      with pioglitazone (Actos Tablets) in in the routine clinical setting in combination with\n      combination with an insulin product in patients with type 2 diabetes mellitus who responded\n      inadequately when using an insulin product in addition to diet therapy and exercise therapy."
        }, 
        "brief_title": "Pioglitazone Tablets Special Drug Use Surveillance \"Combined Use of Insulin Products / Long-term Treatment\"", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance on long-term use of newly co-administered\n      pioglitazone tablets (Actos Tablets) in patients with type 2 diabetes mellitus who have\n      poorly controlled blood glucose when using an insulin product in addition to diet therapy\n      and exercise therapy; this survey is designed to determine the safety and efficacy of\n      long-term use of pioglitazone tablets (Actos Tablets) in in the routine clinical setting in\n      combination with combination with an insulin product (the planned sample size, 1000.) The\n      usual adult dosage is 15 mg of pioglitazone administered orally once daily before or after\n      breakfast. Dose adjustment will be made according to gender, age, and symptoms with an upper\n      limit of 30 mg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with type 2 diabetes mellitus assumed to have insulin resistance who responded\n        inadequately when using an insulin product in addition to diet therapy and exercise\n        therapy who meet the following criteria at enrollment.\n\n          1. Patients treated with an insulin product for at least 4 weeks\n\n          2. Patients who started Actos Tablets for the first time after the start of an insulin\n             product\n\n          3. Patients likely to be available for a 52-week observation and evaluation after the\n             start of co-administration of Actos Tablets\n\n        Exclusion Criteria:\n\n        Patients with contraindications to Actos Tables and insulin products treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Type 2 diabetes mellitus"
            }
        }, 
        "enrollment": {
            "#text": "1067", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068508", 
            "org_study_id": "237-018", 
            "secondary_id": "JapicCTI-132376"
        }, 
        "intervention": {
            "arm_group_label": "Pioglitazone 15 mg to 30 mg, orally, once daily", 
            "description": "Pioglitazone Tablets", 
            "intervention_name": "Pioglitazone", 
            "intervention_type": "Drug", 
            "other_name": "Actos"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pioglitazone", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "February 19, 2014", 
        "number_of_groups": "1", 
        "official_title": "Actos Tablets Special Drug Use Surveillance \"Combined Use of Insulin Products / Long-term Treatment\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Frequency, severity, and time to onset of adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions..", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks from the baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068508"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tabulation and analysis of fasting blood glucose and HbA1c.", 
                "measure": "Changes in glycemia-related parameters (fasting blood glucose, glycosylated hemoglobin [HbA1c])", 
                "safety_issue": "No", 
                "time_frame": "52 weeks from the baseline"
            }, 
            {
                "description": "Tabulation and analysis of fasting triglycerides, HDL cholesterol, and LDL cholesterol)", 
                "measure": "Changes in test values (fasting triglycerides, HDL cholesterol, and LDL cholesterol)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks from the baseline"
            }, 
            {
                "description": "Tabulation and analysis of the daily dose of insulin product.", 
                "measure": "Changes in the daily dose of insulin product", 
                "safety_issue": "No", 
                "time_frame": "52 weeks from the baseline"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}